{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:18:59Z","timestamp":1770142739919,"version":"3.49.0"},"reference-count":23,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2023,12,2]]},"DOI":"10.1080\/14740338.2023.2247962","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T10:25:01Z","timestamp":1692181501000},"page":"1283-1287","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Sublingual\/Buccal buprenorphine and dental problems: a pharmacovigilance study"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1512-1265","authenticated-orcid":false,"given":"Romain","family":"Barus","sequence":"first","affiliation":[{"name":"Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7056-8126","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Montastruc","sequence":"additional","affiliation":[{"name":"Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"de Canecaude","sequence":"additional","affiliation":[{"name":"Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haleh","family":"Bagheri","sequence":"additional","affiliation":[{"name":"Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7980-5650","authenticated-orcid":false,"given":"Agn\u00e8s","family":"Sommet","sequence":"additional","affiliation":[{"name":"Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5494-5873","authenticated-orcid":false,"given":"Maryse","family":"Lapeyre-Mestre","sequence":"additional","affiliation":[{"name":"Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,8,21]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-019-00143-6"},{"key":"e_1_3_5_4_1","unstructured":"Buprenorphine and Naloxone Sublingual Tablets (2 mg\/0.5 mg and 8 mg\/2 mg) (buprenorphine\/naloxone) dose indications adverse effects interactions\u2026 from PDR.net. https:\/\/www.pdr.net\/drug-summary\/Buprenorphine-and-Naloxone-Sublingual-Tablets\u20132-mg-0-5-mg-and-8-mg-2-mg\u2013buprenorphine-naloxone-3772 (consult\u00e9 le 26 jui 2023)."},{"key":"e_1_3_5_5_1","unstructured":"Methadone Hydrochloride Oral Concentrate USP 10 mg per mL(Dye-Free Sugar-Free Unflavored) andMethadone Hydrochloride Oral Concentrate USP 10 mg per mL(Cherry)."},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00742"},{"key":"e_1_3_5_8_1","unstructured":"FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain."},{"key":"e_1_3_5_9_1","unstructured":"A Call for the FDA to Retract its safety communication regarding buprenorphine. 2022."},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/154405910508400703"},{"issue":"5","key":"e_1_3_5_11_1","article-title":"Sugar-containing or sugar-free paediatric medicines: does it really matter?","volume":"21","author":"Mackie IC","year":"1994","unstructured":"Mackie IC, Bentley E. Sugar-containing or sugar-free paediatric medicines: does it really matter?. Dent Update. 1994 jui;21(5):192\u2011194.","journal-title":"Dent Update"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.5005\/jcdp-9-3-1"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0899-9007(02)00836-5"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/009286150804200501"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1742"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.668"},{"key":"e_1_3_5_17_1","unstructured":"Screening-adverse-reactions-eudravigilance_en.pdf. Consult\u00e9 le: 21 f\u00e9v 2023. [En ligne]. Disponible sur: https:\/\/www.ema.europa.eu\/en\/documents\/other\/screening-adverse-reactions-eudravigilance_en.pdf"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13754"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.17485"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.0976"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0575-5"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-051X.1993.tb00374.x"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/205016841700600105"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.13l01533"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15757"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2023.2247962","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T06:47:37Z","timestamp":1702968457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2023.2247962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,21]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,2]]}},"alternative-id":["10.1080\/14740338.2023.2247962"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2023.2247962","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-05-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}